文献速递类风湿关节炎

2型极化T细胞表型与类风湿关节炎甲氨蝶呤无应答相关

Association of a Type 2-Polarized T Cell Phenotype With Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2020-05-29

该研究对32例近期起病的类风湿关节炎(RA)患者给予甲氨蝶呤(MTX)治疗6个月,15例为应答者、17例为无应答者,并在基线和6个月时进行全面的血液T细胞免疫表型分析。基线疾病活动度指标在两组间无差异,但MTX无应答者外周血呈现2型极化T细胞偏移,表现为IL-13+CD4+效应记忆T细胞增多及IL-13+:IL-17+ Tem比值升高。提示靶向IL-13+CD4+ T细胞通路可能成为MTX耐药RA的新治疗策略。

要点

  • 基线DAS28、CRP、ESR不能区分MTX应答与无应答。
  • MTX无应答者IL-13+CD4+效应记忆T细胞显著增多,呈2型偏移。
  • 靶向IL-13+CD4+ T细胞通路或为MTX耐药RA的新策略。

核心结论

  • MTX无应答RA患者外周血存在2型极化T细胞炎症反应偏移,靶向IL-13+CD4+ T细胞通路可能是MTX耐药RA的新治疗策略。

研究设计与样本

  • 研究纳入32例近期起病并接受MTX治疗的RA患者,6个月后15例为应答者、17例为无应答者。
  • 采用多参数免疫荧光流式细胞术,在基线和治疗6个月后进行全面的血液T细胞免疫表型分析。

主要发现

  • 基线DAS28、C反应蛋白水平及红细胞沉降率在MTX应答者与无应答者间无差异。
  • MTX应答者的CD4:CD8 T细胞比值高于无应答者(P < 0.05)。
  • 表达可诱导共刺激分子的Treg细胞比例在MTX无应答者中显著更高。
  • 产生IL-13(而非干扰素-γ或IL-17)的CD4+效应记忆T细胞在MTX无应答者中显著更多(P < 0.05)。
  • CD4+ Tem中IL-13+:IL-17+ Tem比值在无应答者中较应答者高1.9倍(P < 0.05)。

关键数值与推荐

  • CD4:CD8 T细胞比值与IL-13+CD4+ Tem细胞频率均与MTX治疗后DAS28评分变化相关。
  • T细胞免疫检查点抑制剂标志物(CTLA-4、程序性死亡受体1、T细胞免疫球蛋白及黏蛋白结构域蛋白3)表达在应答者与无应答者间无差异。

临床怎么用

  • 对RA患者启动MTX前可考虑T细胞免疫表型评估,识别2型极化特征的无应答高风险人群。
  • 对MTX疗效不佳且呈IL-13+CD4+ T细胞通路偏移者,可探索靶向该通路的治疗策略。

局限性

  • 样本量较小(共32例),结果需更大样本验证。
  • 仅分析外周血T细胞免疫表型,未涉及关节局部免疫微环境。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rheumatoid arthritis (RA) is a chronic inflammatory disease mediated through complex immunologic pathways. Among RA patients receiving low-dose methotrexate (MTX) monotherapy, approximately one-half exhibit a meaningful clinical response within the first 6 months of starting treatment. Whether baseline immune phenotypes differ between subsequent MTX responders and nonresponders is unknown. This study utilized comprehensive T cell immunophenotyping to identify specific immunologic pathways associated with MTX-nonresponsive joint inflammation in patients with RA. METHODS: In total, 32 patients with recent-onset RA were treated with MTX therapy. After 6 months, 15 patients were categorized as responders and 17 as nonresponders. Comprehensive blood T cell immunophenotyping, using multiparameter immunofluorescence flow cytometry analyses, was performed at baseline and following 6 months of treatment. RESULTS: Baseline measures of disease activity (Disease Activity Score in 28 joints [DAS28], C-reactive protein level, and erythrocyte sedimentation rate) did not differ between MTX responders and nonresponders following MTX treatment. Frequencies of CD4+ and CD8+ T cells were skewed to favor higher CD4:CD8 T cell ratios in MTX responders compared to nonresponders (P < 0.05). The proportion of inducible costimulator-expressing Treg cells was significantly greater among MTX nonresponders. Interleukin-13 (IL-13)-producing, but not interferon-γ- or IL-17-producing, CD4+ effector memory T (Tem) cells were significantly more frequent in MTX nonresponders (P < 0.05). The ratio of IL-13+:IL-17+ Tem cells among CD4+ Tem cells was 1.9-fold higher in MTX nonresponders compared to responders (P < 0.05). Both the CD4:CD8 T cell ratio and the frequency of IL-13+CD4+ Tem cells correlated with changes in the DAS28 score following MTX treatment, whereas T cell expression of immune checkpoint inhibitor markers (CTLA-4, programmed death 1, and T cell immunoglobulin and mucin domain-containing protein 3) did not differ between MTX responders and nonresponders. CONCLUSION: We observed a bias toward type 2-polarized T cell inflammatory responses in the peripheral blood of MTX-nonresponsive RA patients. Targeting the IL-13+CD4+ T cell pathway could be a new therapeutic strategy in RA patients whose disease remains resistant to MTX.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Slauenwhite D, McAlpine SM, Hanly JG, et al. Association of a Type 2-Polarized T Cell Phenotype With Methotrexate Nonresponse in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2020. PMID: 32039570. doi:10.1002/art.41223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。